Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.41 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | LCK | P06239 | 1/20 | 0.40 |
| ▸ | PPARD | Q03181 | 1/20 | 0.40 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.40 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.40 |
| ▸ | GRIK1 | P39086 | 2/20 | 0.38 |
| ▸ | GRIK2 | Q13002 | 2/20 | 0.38 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.38 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.38 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.36 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14576719 | 0.93 | CA2 (0.36) | GPR84FFAR1SLC1A2SLC1A1 | |
| SCHEMBL20341607 | 0.92 | GPR84 (0.44) | GPR84FFAR1MAPTLCKPPARD | |
| SCHEMBL23094032 | 0.89 | GPR84 (0.38) | GPR84FFAR1MAPTLCKPPARD | |
| SCHEMBL18595261 | 0.77 | ZDHHC7 (0.37) | GPR84FFAR1MAPTLCKPPARD | |
| SCHEMBL1469950 | 0.77 | CHRM1 (0.38) | — | |
| SCHEMBL29969036 | 0.77 | GRIK1 (0.40) | GPR84FFAR1MAPTLCKPPARD | |
| SCHEMBL27676709 | 0.76 | SLC6A4 (0.35) | GPR84FFAR1MAPTLCKPPARD | |
| SCHEMBL6216939 | 0.75 | FFAR1 (0.50) | GPR84FFAR1FFAR4ACE2 | |
| SCHEMBL9972636 | 0.75 | CYP2C19 (0.39) | — | |
| SCHEMBL13875771 | 0.75 | CA2 (0.37) | GPR84FFAR1FFAR4SLC1A2SLC1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2125029-B1 | CONSTRUCTION AND USE OF TRANSFECTION ENHANCER ELEMENTS | LIPOCALYX GMBH (DE) | 2016-10-12 | — | — | EP | disclosed |
| US-20130011916-A1 | CONSTRUCTION AND USE OF TRANSFECTION ENHANCER ELEMENTS | LIPOCALYX GMBH (DE) | 2013-01-10 | — | — | US | disclosed |
| US-8193246-B2 | Lipids and lipid assemblies comprising transfection enhancer elements | MARINA BIOTECH, INC. (US) | 2012-06-05 | — | — | US | disclosed |
| US-20100022621-A1 | CONSTRUCTION AND USE OF TRANSFECTION ENHANCER ELEMENTS | MDRNA RESEARCH, INC. | 2010-01-28 | — | — | US | disclosed |
| EP-2125031-A2 | LIPIDS AND LIPID ASSEMBLIES COMPRISING TRANSFECTION ENHANCER ELEMENTS | Novosom AG (DE) | 2009-12-02 | — | — | EP | disclosed |
| US-20080306153-A1 | Lipids and lipid assemblies comprising transfection enhancer elements | CEQUENT PHARMACEUTICALS, INC. | 2008-12-11 | — | — | US | disclosed |
| EP-1938843-A1 | Lipids and lipid assemblies comrising transfection enhancer elements | Novosom AG (DE) | 2008-07-02 | — | — | EP | disclosed |
| WO-2008074487-A2 | LIPIDS AND LIPID ASSEMBLIES COMPRISING TRANSFECTION ENHANCER ELEMENTS | NOVOSOM AG (DE) | 2008-06-26 | — | — | WO | disclosed |
| EP-1935434-A1 | Construction and use of transfection enhancer elements | Novosom AG (DE) | 2008-06-25 | — | — | EP | disclosed |
| US-20080145413-A1 | Lipids and lipid assemblies comprising transfection enhancer elements | MARINA BIOTECH, INC. | 2008-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080145413-A1 | Lipids and lipid assemblies comprising transfection enhancer elements | HNRNPH3, SREBF2, PHOSPHO1 | GPR84 4066/4885FFAR1 1661/4885MAPT 3292/4885 |
| US-20100022621-A1 | CONSTRUCTION AND USE OF TRANSFECTION ENHANCER ELEMENTS | TEAD4, CREB1, ELF3 | GPR84 3273/4885FFAR1 3622/4885MAPT 4859/4885 |
| US-20080306153-A1 | Lipids and lipid assemblies comprising transfection enhancer elements | SREBF1, SREBF2, ELOVL1 | GPR84 3559/4885FFAR1 1005/4885MAPT 4673/4885 |
| US-20130011916-A1 | CONSTRUCTION AND USE OF TRANSFECTION ENHANCER ELEMENTS | TEAD4, CREB1, ELF3 | GPR84 3273/4885FFAR1 3622/4885MAPT 4859/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.